Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
Phase 2
Completed
- Conditions
- Metastatic Skin Squamous Cell CarcinomaRecurrent Skin Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT01198028
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Behavioral: Cancer Symptom QuestionnaireOther: Biomarker Testing
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1275
- Registration Number
- NCT01196130
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Social Contextual Influences on Physical Activity
- Conditions
- CancerPrevention Harmful Effects
- Interventions
- Behavioral: PA Prescription PlanDevice: PedometerBehavioral: Newsletters
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 336
- Registration Number
- NCT01195337
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Azacitidine and CAPOX in Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01193517
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Ipilimumab in Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01194271
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
Phase 2
Terminated
- Conditions
- Advanced Cancers
- Interventions
- Other: Dim Red Light TherapyOther: Bright Light TherapyBehavioral: QuestionnairesBehavioral: Study DiariesDevice: Bright Light LitebookDevice: Red Light Litebook
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT01193530
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Terminated
- Conditions
- Skin Cancer
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01193036
- Locations
- πΊπΈ
UT MD Anderson Cancer Center, Houston, Texas, United States
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01191749
- Locations
- πΊπΈ
UT MD Anderson Cancer Center, Houston, Texas, United States
SCH-900105 in Recurrent Glioblastoma
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01189513
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 278
- Registration Number
- NCT01187199
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States